Insilico Medicine

NEW Video ?? Insilico Deployed the First Bipedal Humanoid at the AI-Powered Fully-Robotic Lab The humanoid, called “Supervisor” will be used for #dataacquisition and data generation for training of the embodied #AIsystems to learn the skills of human laboratory scientists. The work will be conducted by the Insilico Robotics team at Insilico Medicine. The humanoid will also immediately assist with lab tours, telepresence, tracking and lab supervision. Watch the video here ?? https://lnkd.in/eJZ4ekrk

?? We’re thrilled to share that Alex Zhavoronkov, Founder & CEO of Insilico Medicine, will be a guest speaker at the Private Wealth Sessions during the HSBC Global Investment Summit 2025! ?? ?? What to Expect: ? The role of AI in drug discovery & longevity science ? The intersection of biotech innovation & global investment ? How AI-driven platforms like Pharma.AI are reshaping the future of medicine We will share perspectives on AI’s impact on the industry — what’s working, what’s not, and where real progress is happening in healthcare and biotech. Looking forward to the discussion! #HSBCGIS #HSBCGlobalSummit #ThePrivateWealthSessions

Listen On-Demand! ??? Exciting discussions at #HumanX2025 on how AI and generative biology are transforming drug discovery! The convergence of AI, automation, and biotech is paving the way for faster, smarter, and more effective therapeutics. Thank you to the HumanX #HumanX2025 team, and CEO Michael Nally of Generate:Biomedicines.

In July 2024, we launched DORA, the multi-agent researcher and paper drafter (Alex Philippidis covered it first). I always like to give credit to Marinka Zitnik's group who put out the perspective on multi-agent research before deep research, manus, etc. DORA was used by over a thousand researchers so far and we put out the pre-print with some learnings. Please check it out. Journal editors interested in this story, please ping us to see if you would like to consider it. This tool was used in many different applications from biotech for which it was developed to petro and agrichemistry. We can now hook it up to fully-automated labs and will soon try the humanoid in the loop. https://lnkd.in/gRtKCZ35

Are you attending Bio-IT World 2025 in Boston? If so, you won’t want to miss three of the leading voices in AI-driven drug discovery: ?? Dr. Petrina Kamya, Ph.D. – Global Head of AI Platforms, VP, Insilico Medicine Canada ?will present “Revolutionizing Drug Discovery with Generative AI” on April 3, and will join the “Unlocking AI Potential: Best Practices for Implementation and Management” panel on April 4. ?? Dr. Alex Zhavoronkov – Founder & CEO, Insilico Medicine, will lead the “PLENARY KEYNOTE PRESENTATION: Generative AI, Aging Research and Robotics as a Platform for Drug Discovery: From Hype to Clinical Efficacy” on April 3. ?? Dr. Michelle Chen – Chief Business Officer, Insilico Medicine, will be part of this “PANEL DISCUSSION: Optimizing Investment Strategies in Biotech” on April 3, as part of the Bio-IT World Venture, Innovation & Partnering event. Be sure to add their talks to your agenda and visit us at the Omni Hotel Seaport to explore how AI is shaping the future of drug discovery and development. Email our team or connect with us here! [email protected] [insilico.com] ?? Register here: https://lnkd.in/eQdHu7E3

I always enjoy attending #BIOEurope. Not only do #EBD Group choose the best cities in Europe to host the events, but also the diversity of topics are interesting. This year’s #BIOEuropeSpring in Milan is no exception. All together Insilico Medicine had close to 60 meetings with #Pharma, #biotech and #investors. What a great opportunity to catch up with old friends/colleagues, and make new ones! Monika Vnuk Mathias Falcenberg Hubert Birner Nikolaus Krall Miha Stajdohar Friedrich von Bohlen Michelle Cheesbrough Avisha Amalean Claire Macht Sarah Holland Victoria Balannik Elisa Manca Ricardo Gaminha Pacheco Jan Szollos, MBA Linda Pullan Luca Bolliger kristin rookey Angele Maki David Madge Hui Cai Jesús Baena Sanna McMullen Antti Haapalinna

?? The Future of Scientific Writing is Here! ?? A recent Springer Nature Biotechnology article explores the evolving role of AI in scientific writing, highlighting its potential to enhance research communication, speed up manuscript preparation, and reduce barriers for scientists worldwide. ?? Read the Nature article here: An open letter to graduate students and other procrastinators: it’s time to write [https://lnkd.in/dqxsDF3R] At Insilico Medicine, we’re at the forefront of this transformation with Science42 #DORA – an AI-powered writing assistant designed to help scientists, researchers, and academics craft compelling #abstracts, #manuscripts, and #grantproposals with greater efficiency. ?? Whether you're preparing for a conference, submitting a journal paper, or applying for funding, DORA streamlines the process, ensuring high-quality, well-structured content. ??? Learn more about Science42 DORA: https://bit.ly/4c0WO0B

We’re thrilled to have Alex Zhavoronkov, PhD, Petrina Kamya, Ph.D. and Michelle Chen, PhD, take the stage at #BioITWorld2025 in Boston to discuss how #AI and Pharma.AI are transforming drug discovery, precision medicine, and longevity research! ?? The Bio-IT World Conference & Expo is the premier global event showcasing technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. ?? Join us in Boston to explore the future of AI-powered drug discovery and meet our team of experts pushing the boundaries of science! ?? Read more: https://lnkd.in/d-M45Y7J #BioITWorld #AIinBiotech #PharmaAI #DrugDiscovery #LongevityScience #AIforHealthcare #InsilicoMedicine

?? Insilico Medicine is headed to #AACR25 in Chicago! ??? AACR Journals ?? Booth 334 | April 25-30 | McCormick Place Convention Center ?? Meet our experts: ? Dr. Petrina Kamya, Ph.D. Kamya – Global Head of AI Platforms & VP, Insilico Medicine Canada, will showcase how Pharma.AI accelerates drug discovery with cutting-edge AI for target identification, generative chemistry, and more. ? Dr. Michelle Chen – Chief Business Officer, will be on-site to discuss partnership opportunities and how Insilico’s AI-driven pipeline is transforming the biopharma industry. ?? Whether you’re exploring AI-driven research or looking for new partnerships, stop by Booth 334 to connect with our team! ?? Learn more: https://bit.ly/4j0LvYA #AIforCancerResearch #AACR2025 #PharmaAI #DrugDiscovery #Biotech #InsilicoMedicine

Thank you to AiNews.com - Company Page for hosting Alex Zhavoronkov at the 2025 #HumanX Conference to explore how AI-powered drug discovery is revolutionizing #biopharma, #aging research, and the future of human health. https://lnkd.in/ew3_j3HD ?? Highlights: ? AI-Driven Drug Discovery – How Insilico’s generative AI models are transforming the drug development pipeline ? Fighting Aging & Disease – Why Insilico targets aging as the root cause of multiple diseases ? Clinical Success – The journey behind Insilico’s AI-designed drug advancing through Phase 2A trials ? Robotics in Biotech – How fully autonomous labs and humanoid robots optimize R&D ? Quantum Computing – The future role of quantum tech in molecular generation ? Global Collaboration – Why Insilico sees China as a key partner in accelerating drug testing and development ? Longevity Research – How AI could unlock longer, healthier lives for future generations